Educational afterwork with CMC focus

Join CCRM Nordic together with partners GU Ventures New Modality Support and SCALE (our workforce development initiative funded by Västra Götalandsregionen and the European Union) for an educational after-work focused on ATMP product development and the regulatory changes shaping how therapies are brought to market, including updates to the Common Technical Document (CTD).

🎤 Featuring Andrew Willis (@StemSight / @LIfT BioSciences), who will unpack what the new ICH M4 revisions mean in practice, from CMC requirements to quality control strategy and marketing authorisation readiness.

💡 Why it matters:
Understanding the evolving CTD is critical to avoid inefficiencies and delays in approval, as well as to build a robust path to market.

Agenda highlights:
16:15 Welcome
16:30 Presentation + Q&A
17:30 Networking over drinks & nibbles